Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Patent
1995-06-07
2000-07-11
Guzo, David
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
4353201, 4353722, 424 932, C12N 1585, C12N 510, C12N 1512
Patent
active
060871784
ABSTRACT:
Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4419446 (1983-12-01), Howley et al.
patent: 4601978 (1986-07-01), Karin
patent: 4656134 (1987-04-01), Ringold
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5359032 (1994-10-01), Dayer et al.
Verma et al., Nature, vol. 389, pp. 239-242, Sep. 18, 1997.
Carter, et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein," Nature 344:633-368 (Apr. 12, 1990).
Cominelli, et al., "Interleukin 1 (IL-1) Gene Expression, Synthesis, and Effect of Specific IL-1 Receptor Blockade in Rabbit Immune Complex Colitis," J. Clin. Invest., 86:872-980 (Sep. 1990).
Dinarello, et al., "Multiple Biological Activities of Human Recombinant Interleukin 1," J. Clin. Invest., 77:1734-1739 (Jun. 1986).
Eisenberg, et al., "Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist," Nature, 343:341-346, (Jan. 25, 1990).
Fanslow, et al., "Regulation of Alloreactivity in Vivo by a Soluble Form of the Interleukin-1 Receptor," Science, 248:739-742, (May 1990).
Gosset, et al., "Production of an Interleukin-1 Inhibitor Factor by Human Alveolar Macrophages from Normals and Allergic Asthmatic Patients," Am. Rev. Respir. Dis., 138:40-46 (1988).
Gershenwald, et al., "Interleukin 1 receptor blockade attenuates the host inflammatory response," Proc. Natl. Acad. Sci. USA, 87:4966-4970 (Jul. 1990).
Hannum, et al., "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor," Nature, 343:336-339 (Jan. 25, 1990).
Maliszewski, et al., "Cytokine Receptors and B Cell Functions-1. Recombinant Soluble Receptors Specifically Inhibit IL-1-and IL-4-Induced B Cell Activities in Vitro," The Journal of Immunology, 144:3028-3033, No.8 (Apr. 15, 1990).
Oppenheim, et al., "There is More Than One Interleukin 1," Immunology Today, Reviews, 7:45-56 No. 2 (1986).
Palaszynski, "Synthetic C-Terminal Peptide of IL-1 functions as a Binding Domain As Well As An Antagonist For The IL-1 Receptor," Biochemical and Biophysical Research Communications, 147:204-211, No. 1 (Aug. 31, 1987).
Seckinger, et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1.alpha. and 1.beta. But Not Tumor Necrosis Factor .alpha.," The Journal of Immunology, 139:1541-1545, No. 5 (Sep. 1, 1987).
Travis, J., "Mutant Gene Explains Some HIV Resistance," Science News, 150:103, (Aug. 17, 1996).
Liu, et al., "Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection," Cell 86:367-377 (Aug. 8, 1996).
Simpson, et al., "Reduction of Experimental Canine Myocardial Reperfusion Injury by a Monoclonal Antibody (Anti-Mol, Anti-CD11b) That Inhibits Leukocyte Adhesion," J. Clin. Invest., 81:624-629 (Feb. 1988).
Dorland's Illustrated Medical Dictionary, 24th Ed., W.B. Saunders Company, Philadelphia, PA., p. 760, defining "ischemia," (1965).
Vedder, et al., "A Monoclonal Antibody to he Adherence-promoting Leukocyte Glycoprotein, CD18, Reduces Organ Injury and Improves Survival from Hemorrhagic Shock and Resuscitation in Rabbits," J. Clin. Invest., 81:939-944 (1988).
Cotran, et al., "Induction and Detection of a Human Endothelial Activation Antigen In Vivo," Brief Definitive Report, J. Exp. Med. 164: 661-666, (Aug. 1986).
Buchan, et al., "Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1.alpha.," Clin. Exp. Immunol. 73:449-455 (Mar. 1988).
Haskill John Stephen
Ralph Peter
Blackburn Robert P.
Chiron Corporation
Guzo David
LandOfFree
Method for down regulating CD4 expression in a T cell does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for down regulating CD4 expression in a T cell, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for down regulating CD4 expression in a T cell will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-541361